PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
0.07 - 0.07
0.04 - 0.15
840.0K / 2.59M (Avg.)
-2.33 | -0.03
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
-15.37%
Negative revenue growth while 8095.HK stands at 37.49%. Joel Greenblatt would look for strategic missteps or cyclical reasons.
-20.11%
Negative gross profit growth while 8095.HK is at 4.42%. Joel Greenblatt would examine cost competitiveness or demand decline.
-28.33%
Negative EBIT growth while 8095.HK is at 1331.35%. Joel Greenblatt would demand a turnaround plan focusing on core profitability.
-29.83%
Negative operating income growth while 8095.HK is at 5589.61%. Joel Greenblatt would press for urgent turnaround measures.
7.11%
Net income growth under 50% of 8095.HK's 3271.43%. Michael Burry would suspect the firm is falling well behind a key competitor.
6.33%
EPS growth under 50% of 8095.HK's 3233.33%. Michael Burry would suspect deeper structural issues or share dilution limiting per-share gains.
6.33%
Diluted EPS growth under 50% of 8095.HK's 3233.33%. Michael Burry would worry about an eroding competitive position or excessive dilution.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-15.52%
Both companies have negative long-term revenue/share growth. Martin Whitman would question if the entire market or product set is shrinking.
-36.82%
Both face negative 5Y revenue/share CAGR. Martin Whitman would suspect macro headwinds or obsolete product offerings across the niche.
-40.84%
Negative 3Y CAGR while 8095.HK stands at 35.55%. Joel Greenblatt would look for missteps or fading competitiveness that hurt sales.
738.15%
Positive long-term OCF/share growth while 8095.HK is negative. John Neff would see a structural advantage in sustained cash generation.
No Data
No Data available this quarter, please select a different quarter.
66.25%
3Y OCF/share CAGR of 66.25% while 8095.HK is zero. Bruce Berkowitz might see if small gains can expand into a broader advantage.
-8.55%
Negative 10Y net income/share CAGR while 8095.HK is at 2219.35%. Joel Greenblatt sees a major red flag in long-term profit erosion.
-881.13%
Negative 5Y net income/share CAGR while 8095.HK is 220.23%. Joel Greenblatt would see fundamental missteps limiting profitability vs. the competitor.
-879.87%
Negative 3Y CAGR while 8095.HK is 603.40%. Joel Greenblatt might call for a short-term turnaround strategy or cost realignment.
No Data
No Data available this quarter, please select a different quarter.
-25.09%
Negative 5Y equity/share growth while 8095.HK is at 91.00%. Joel Greenblatt sees the competitor building net worth while this firm loses ground.
66.77%
3Y equity/share CAGR above 1.5x 8095.HK's 21.82%. David Dodd verifies the company’s short-term capital management far exceeds the competitor’s pace.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-23.54%
We cut SG&A while 8095.HK invests at 3.77%. Joel Greenblatt sees a short-term margin benefit but wonders if the competitor invests for future gains.